Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
An update from Radiopharm Theranostics Limited ( (AU:RAD) ) is now available.
Radiopharm Theranostics reported second interim results from its U.S. Phase 2b imaging trial of RAD101 in brain metastases, showing 90% concordance between RAD101 PET imaging and MRI in 18 of 20 evaluable patients, meeting the study’s primary endpoint. Early six‑month follow‑up and biopsy data from the first five patients also indicate a positive trend in sensitivity and specificity, reinforcing RAD101’s potential to address diagnostic limitations of conventional MRI in the growing population of patients with intracranial metastatic disease and supporting the company’s plans to progress toward a pivotal trial.
The most recent analyst rating on (AU:RAD) stock is a Hold with a A$0.02 price target. To see the full list of analyst forecasts on Radiopharm Theranostics Limited stock, see the AU:RAD Stock Forecast page.
More about Radiopharm Theranostics Limited
Radiopharm Theranostics Limited is a clinical‑stage biopharmaceutical company developing innovative oncology radiopharmaceuticals that target areas of high unmet medical need. The company focuses on small‑molecule imaging agents, such as RAD101, designed to improve diagnosis and treatment decision‑making for patients with solid tumors and brain metastases.
Average Trading Volume: 3,227,998
Technical Sentiment Signal: Sell
Current Market Cap: A$70.88M
For a thorough assessment of RAD stock, go to TipRanks’ Stock Analysis page.